Teacher Retirement System of Texas Sells 2,990 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Teacher Retirement System of Texas reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,837 shares of the company’s stock after selling 2,990 shares during the period. Teacher Retirement System of Texas’ holdings in Neurocrine Biosciences were worth $3,009,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of NBIX. First Horizon Advisors Inc. raised its holdings in shares of Neurocrine Biosciences by 10.5% in the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after acquiring an additional 74 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Neurocrine Biosciences by 34.3% in the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares during the last quarter. Red Spruce Capital LLC grew its holdings in Neurocrine Biosciences by 0.6% during the fourth quarter. Red Spruce Capital LLC now owns 16,026 shares of the company’s stock worth $2,112,000 after buying an additional 101 shares in the last quarter. Finally, Metis Global Partners LLC raised its position in Neurocrine Biosciences by 4.7% in the 3rd quarter. Metis Global Partners LLC now owns 2,361 shares of the company’s stock valued at $266,000 after buying an additional 106 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $138.48 on Wednesday. The firm has a market cap of $13.94 billion, a P/E ratio of 38.15 and a beta of 0.28. The business’s 50 day moving average price is $138.17 and its 200-day moving average price is $130.51. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $148.37.

Insiders Place Their Bets

In other news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the sale, the director now owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,164 shares of company stock worth $23,078,442. 4.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on NBIX shares. JPMorgan Chase & Co. upped their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Mizuho raised their price target on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, February 8th. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $148.96.

View Our Latest Report on Neurocrine Biosciences

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

See Also

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.